COMMENTARY

• New Generic Listings Plunge, Industry Heads for a Shakeout
  July 1, 2026

• Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
  June 16, 2026

• 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
  June 9, 2026

• Are Technical Discussions Enough for Japan’s CEA System?
  May 25, 2026

• Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
  April 28, 2026

• Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
  April 24, 2026

• Challenges in a Post-AG Era: Ensuring a Reliable Supply System
  April 6, 2026

• Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
  April 1, 2026

• A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
  March 24, 2026

• Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
  March 11, 2026

• Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
  March 10, 2026

• ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
  March 9, 2026

• G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
  February 25, 2026

• Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
  February 18, 2026

• Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
  February 9, 2026

• Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
  February 5, 2026

• TSE’s Growth Market Reform Puts Pressure on Biotechs
  January 27, 2026

• Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
  January 6, 2026

• Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
  December 22, 2025

• FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
  December 9, 2025

ページ